The European Journal of Health Economics

, Volume 7, Issue 4, pp 247–254 | Cite as

Cost-benefit analysis of a plant sterol containing low-fat margarine for cholesterol reduction

  • A. Gerber
  • T. Evers
  • H. Haverkamp
  • K. W. Lauterbach

Abstract

For decreasing the risk of coronary heart disease (CHD) it has been proposed to enrich food such as margarine with plant sterol esters which have been shown to reduce total and LDL cholesterol concentrations, two of the major risk factors. A Markov model was developed to assess the costs and benefits of consuming a low-fat plant sterol containing margarine (PS margarine). A health insurer’s perspective was taken with a time frame of 10 years. Transition probabilities for CHD and CHD-related death were calculated on the basis of the Framingham risk equations. These were applied to a representative sample of the German population. The alteration in cholesterol levels after intake of PS margarine was estimated based on a meta-analysis of ten randomized controlled trials with parallel or crossover design that found a reduction of 5.7% in total cholesterol. Average annual costs of CHD were assumed to be at €3,000. Costs for “no CHD” and “CHD-related death” were set to €0 since the intervention would solely be paid by the consumers. Sensitivity analyses were performed with regard to annual costs, risk estimation, PS margarine reduction in total cholesterol, discount factor, and risk of CHD-related death. The 10-year CHD risks are 6.1% (PS margarine) vs. 6.5% (control). Thus expected 10-year CHD costs are €696 (PS margarine) vs. €748 (control). The cost savings of €52 varied between €32 and €74 in the sensitivity analysis. A projection at the level of the population for which evidence (randomized controlled trials) exists that plant sterols lower cholesterol (25.35 million) leads to a reduction of 117,000 CHD cases over 10 years and a cost reduction of €1.3 billion for this time period (sensitivity analysis €0.8–1.9 billion).

Keywords

Cholesterol reduction Coronary heart disease Cost-benefit analysis Low-fat margarine Low-fat plant sterol 

References

  1. 1.
    Hinzpeter B, Klever-Deichert G, Wendland G, Lauterbach KW (2000) Die koronare Herzkrankheit und die Sozialversicherung. Herz 25: 515–525CrossRefPubMedGoogle Scholar
  2. 2.
    Wiesner G, Grimm J, Bittner E (1999) Zum Herzinfarktgeschehen in der Bundesrepublik Deutschland: Prävalenz, Inzidenz, Trend, Ost-West-Vergleich. Gesundheitswesen 61: S72–S78PubMedGoogle Scholar
  3. 3.
    Klever-Deichert G, Hinzpeter B, Wendland G, Lauterbach KW (2000) Kosten-Nutzen-Analyse einer evidenzbasierten Sekundärprävention koronarer Herzkrankheiten durch Statine. Med Klin 95: 305–313CrossRefGoogle Scholar
  4. 4.
    Anonymous (2002) Morbidity & mortality: 2002 chart book on cardiovascular, lung, and blood diseases. Health NIo.Google Scholar
  5. 5.
    Anderson KM, Odell PM, Wilson PWF, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121: 293–298CrossRefPubMedGoogle Scholar
  6. 6.
    Assmann G, Schulte H (1990) Modelling the Helsinki Heart Study by means of risk equations obtained from the PROCAM Study and the Framingham Heart Study. Drugs 40: 13–18PubMedGoogle Scholar
  7. 7.
    Wood D, De Backer G, Faergeman O et al. (1998) Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 140: 199–270CrossRefPubMedGoogle Scholar
  8. 8.
    Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (2002) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): National Heart, Lung, and Blood Institute. National Institutes of HealthGoogle Scholar
  9. 9.
    Grundy SC, Balady GJ, Criqui MH et al. (1998) Primary prevention of coronary heart disease: guidance from Framingham. Circulation 97: 1876–1887PubMedGoogle Scholar
  10. 10.
    Sowers JR, Reed J (2000) 1999 Clinical advisory treatment of hypertension and diabetes. J Clin Hypertens 2: 132–133Google Scholar
  11. 11.
    Berlin J, Colditz G (1990) A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 132: 612–628PubMedGoogle Scholar
  12. 12.
    Eaton CB (1992) Relation of physical activity and cardiovascular fitness to coronary heart disease. I. A meta-analysis of the independent relation of physical activity and coronary heart disease. J Am Board Fam Pract 5: 31–42PubMedGoogle Scholar
  13. 13.
    Hooper L, Summerbell CD, Higgins JPT, Thompson RL, Capps NE, Smith GD et al (2001) Dietary fat intake and prevention of cardiovascular disease: systematic review. BMJ 322: 757–763CrossRefPubMedGoogle Scholar
  14. 14.
    Schaefer EJ (2002) Lipoproteins, nutrition, and heart disease. Am J Clin Nutr 75: 191–212PubMedGoogle Scholar
  15. 15.
    Tang JL, Armitage JM, Lancaster T et al. (1998) Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 316 1213–1220Google Scholar
  16. 16.
    Cater NB, Grundy SM (1998) Lowering serum cholesterol with plant sterols and stanols. Historical perspectives. Postgrad Med [Special Report]: 5–14Google Scholar
  17. 17.
    Ling WH, Jones PJ (1995) Dietary phytosterols: a review of metabolism, benefits and side effects. Life Sci 57: 195–206PubMedGoogle Scholar
  18. 18.
    Ostlund RE Jr (2002) Phytosterols in human nutrition. Annu Rev Nutr 22: 533–549PubMedGoogle Scholar
  19. 19.
    Salen G, Ahrens EH, Grundy SM (1970) Metabolism of beta-sitosterol in man. J Clin Invest 49: 952–967PubMedGoogle Scholar
  20. 20.
    McGee D, Gordon T (2000) The Framingham Study applied to four other U.S. based epidemiological studies of cardiovascular disease. United States Department of Health, Education and Welfare, NIH, Framingham Study, section no. 31: 1976Google Scholar
  21. 21.
    Bellach BM, Knopf H, Thefeld W (1998) Der Bundes-Gesundheitssurvey 1997/98. Gesundheitswesen 60 [Suppl 2]: S59–S68Google Scholar
  22. 22.
    Thierfelder W, Seher CH, Thefeld W (1998) Der Bundes-Gesundheitssurvey. 1997/98-Untersuchungsteil. Gesundheitswesen 60 [Suppl 2]: S69–S77Google Scholar
  23. 23.
    Ntanios F (2001) Spreads enriched with plant sterol esters lower blood total and LDL cholesterol but not HDL cholesterol levels: a meta-analysis of Unilever studies. Vlaardingen: Unilever ResearchGoogle Scholar
  24. 24.
    Ayesh R, Weststrate JA, Drewitt PN, Hepburn PA (1999) Safety evaluation of phytosterol esters. V. Faecal short-chain fatty acid and microflora content, faecal bacterial enzyme activity and serum female sex hormones in healthy normolipidaemic volunteers consuming a controlled diet either with or without a phytosterol ester-enriched margarine. Food Chem Toxicol 37: 1127–1138CrossRefPubMedGoogle Scholar
  25. 25.
    Hendriks HF, Brink EJ, Meijer GW et al. (2003) Safety of long-term consumption of plant sterol esters-enriched spread. Eur J Clin Nutr 57: 681–692CrossRefPubMedGoogle Scholar
  26. 26.
    Jones PJ, Raeini-Sarjaz M, Ntanios FY et al. (2000) Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters. J Lipid Res 41: 697–705PubMedGoogle Scholar
  27. 27.
    Maki KC, Davidson MH, Umporowicz DM et al. (2001) Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program step I diet. Am J Clin Nutr 74: 33–43PubMedGoogle Scholar
  28. 28.
    Mussner MJ, Parhofer KG, Von Bergmann K et al. (2002) Effects of phytosterol ester-enriched margarine on plasma lipoproteins in mild to moderate hypercholesterolemia are related to basal cholesterol and fat intake. Metabolism 51: 189–194CrossRefPubMedGoogle Scholar
  29. 29.
    Neil HA, Meijer GW, Roe LS (2001) Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread. Atherosclerosis 156: 329–337CrossRefPubMedGoogle Scholar
  30. 30.
    Noakes M, Clifton P, Ntanios F et al. (2002) An increase in dietary carotenoids when consuming plant sterols or stanols is effective in maintaining plasma carotenoid concentrations. Am J Clin Nutr 75: 79–86PubMedGoogle Scholar
  31. 31.
    Tijburg L, Meijer G, Rudrum M, Ntanios F (2001) Plant sterol-esters in a low fat spread are efficacious in lowering blood cholesterol levels in normal cholesterolemic subjects. FASEB J 15: A397Google Scholar
  32. 32.
    Weststrate JA, Meijer GW (1998) Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr 52: 334–343PubMedGoogle Scholar
  33. 33.
    Hwang JS (1999) Monte Carlo estimation of extrapolation of quality-adjusted survival for follow-up studies. Stat Med 18: 1627–1640CrossRefPubMedGoogle Scholar
  34. 34.
    Wendland G (2002) Kosteneffektivitätsanalyse der Statintherapie zur Primärprävention der koronaren Herzkrankheit in Deutschland. Thesis, University of CologneGoogle Scholar
  35. 35.
    Ruckdäschel S, Berger K, Szucs T (1996) Koronare Herzkrankheit – ein sozioökonomisches Problem? Munch Med Wochenschr 138: 40–44Google Scholar
  36. 36.
    Pearce KA, Furberg CD, Psaty BM, Kirk J (1998) Cost-minimization and the number needed to treat in uncomplicated hypertension. Am J Hypertens 11: 618–629CrossRefPubMedGoogle Scholar
  37. 37.
    Katan MB, Grundy SM, Jones P et al., for the Stresa Workshop Participants (2003) Efficacy and safety of plants stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 78: 965–978PubMedGoogle Scholar
  38. 38.
    Pollak OJ (1985) Effects of plant sterols on serum lipids and atherosclerosis. Pharmacol Ther 31: 177–208CrossRefPubMedGoogle Scholar
  39. 39.
    Hendriks HF, Weststrate JA, van Vliet T, Meijer GW (1999) Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr 53: 319–327CrossRefPubMedGoogle Scholar
  40. 40.
    Scientific Committee on Food (SCF) (2002) General view of the Scientific Committee on Food on the long-term effects of the intake of elevated levels of phytosterols from multiple dietary sources, with particular attention to the effects on β-carotene. http://europa.eu.int/comm/food/fs/sc/scf/index_en.html, accessed 26 September 2002
  41. 41.
    Awad AB, Fink CS (2000) Phytosterols as anticancer dietary components: evidence and mechanism of action. J Nutr 139: 2127–2130Google Scholar
  42. 42.
    Normen L, Andersson SW (2004) Does phytosterol intake affect the development of cancer? In: Dutta PC (ed) Phytosterols as functional food components and nutraceuticals. Nutraceutical science and technology. New York: DekkerGoogle Scholar
  43. 43.
    Assmann G, Paul Cullen P, Erbey J et al. (2005) Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular Munster (PROCAM) study. Nutr Metab Cardiovasc Dis 15: 373–381CrossRefPubMedGoogle Scholar
  44. 44.
    Glueck CJ, Speirs J, Tracy T et al. (1991) Relationships of serum plant sterols (phytosterols) and cholesterol in 595 hypercholesterolaemic subjects, and familial aggregation of phytosterols, cholesterol, and premature coronary heart disease in hyperphytosterolaemic probands and their first-degree relatives. Metabolism 40: 842–848CrossRefPubMedGoogle Scholar
  45. 45.
    Sutherland WHF, Williams WJA, Nye ER et al. (1998) Associations of plasma noncholesteriol sterol levels with severity of coronary artery disease. Nutr Metab Cardiovasc Dis 8: 386–391Google Scholar
  46. 46.
    Rajaratnam RA, Gylling H, Miettinen TA (2000) Independent association of serum squalene and noncholesterol sterol with coronary artery disease in postmenopausal women. J Am Coll Cardiol 35: 1185–1191CrossRefPubMedGoogle Scholar
  47. 47.
    Sudhop T, Gottwald BM, Bergmann K von (2002) Serum plant sterols as a potential risk factor for coronary heart disease. Metabolism 51: 1519–1521CrossRefPubMedGoogle Scholar
  48. 48.
    Wilund KR, Yu L, Xu F et al. (2004) No association between plasma levels of plant sterols and atherosclerosis in mice and men. Arterioscler Thromb Vasc Biol 24: 2326–2332CrossRefPubMedGoogle Scholar
  49. 49.
    Lauterbach KW, Gerber A, Stollenwer B et al. (2005/2006) Die Bedeutung der Therapie mit Lipidsenkern für die kardiovaskuläre Prävention aus gesundheitsökonomischer Sicht. In: Bundesärztekammer (ed) Fortschritte und Fortbildung in der Medizin, vol 29. Cologne: Deutscher Ärzte, pp 236–244Google Scholar
  50. 50.
    Simons LA (2002) Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol 90: 737–740CrossRefPubMedGoogle Scholar
  51. 51.
    Phillips C, Belsey J, Shindler J (2000) Flora proactiv: a clinical and financial impact analysis. J Med Econ 3: 61–76Google Scholar
  52. 52.
    Law M (2000) Plant sterol and stanol margarines and health. BMJ 320: 861–864CrossRefPubMedGoogle Scholar
  53. 53.
    Law MR, Wald NJ, Thompson SG (1994) By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 308: 367–372PubMedGoogle Scholar
  54. 54.
    Lichtenstein AH, Deckelbaum RJ (2001) AHA Science Advisory. Stanol/sterol ester-containing foods and blood cholesterol levels. A statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation 103: 1177–1179PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  • A. Gerber
    • 1
    • 2
  • T. Evers
    • 1
  • H. Haverkamp
    • 1
  • K. W. Lauterbach
    • 1
  1. 1.Institute of Health Economics and Clinical EpidemiologyUniversity of CologneGermany
  2. 2.Institute of Health Economics and Clinical EpidemiologyUniversity of CologneCologneGermany

Personalised recommendations